Background: There have been many reports on the prevalence and incidence of age-related macular degeneration (AMD), and there are some systematic reviews reporting on the pooled prevalence of AMD. However, there is no systematic review of incidence or progression of AMD worldwide. Given the few evidences regarding the pooled incidence or progression of AMD, we performed this meta-analysis protocol to investigate the global incidence or progression of AMD. In addition, we will investigate the risk factors for AMD incidence or progression using meta-analysis.
Introduction
With the increasing numbers of people living longer, the number of people with age-related diseases is rising worldwide. Agerelated macular degeneration (AMD) is a common age-related disease which is also a leading cause of visual impairment and severe vision loss. [1] To date, prevalence of AMD is likely to increase due to exponential population ageing. [2] There have been some studies on the incidence and prevalence of AMD, with systemic reviews summarizing global estimates of its prevalence across regions. [2] Moreover, there is 1 report on late-AMD incidence among American Whites [3] which showed annual incidence of late AMD was 3.5 per 1000 aged ≥50 years. In particular, there is no systematic review of incidence or progression of AMD worldwide and little is known about the incidence and progression of early stage of AMD and the disease in other parts of population apart from American Whites. Furthermore, interpreting incidence estimates from different studies on the incidence of AMD is challenging because of significant variation in its estimates between ethnicities and regions, due to differences in study setting, method of ascertainment of AMD, and follow-up time trends. Robust data SZ and XL contributed equally to this work.
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on incidence and progression of AMD are important for development of major public health strategies to prevent this disease.
To address this gap, we conducted a systematic review and meta-analysis to estimate the global incidence or progression of AMD, and to describe variations by ethnicity, region, study characteristics, and follow-up time period in which the studies were conducted.
Methods

Design and reporting
This systematic review will be designed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. [4] For current protocol, the PRISMA statement for Protocols (PRISMA-P) was used for its description (Table 1) . [5] This systematic review is registered in the PROSPERO International Prospective Register of systematic reviews with number CRD42019118832.
Data source and search strategy
Published primary studies will be gathered using four English databases (PubMed, EMBASE, Cochrane Library, and Web of Science) and four Chinese databases (CMB, CNKI, VIP, and Wanfang database). References of the relevant articles will be searched by hand. Moreover, for article which is difficulty accessing sufficient data or full text, its corresponding author will be contacted by e-mail. The key search terms will be "incidence," "development," "associated factors," "progression,"' and "agerelated macular degeneration." Using all these terms, relevant topics will be searched through 'All fields' using the connecting 'AND' and 'OR' as appropriate.
Inclusion criteria
Type of studies: prospective or retrospective cohort studies.
Type of participants: population over 40 years old. Type of outcome: incidence or progression (or studies giving enough data to compute these estimates if not directly calculated) of AMD.
Language: English or Chinese.
Exclusion criteria
Type of studies: case-control studies, cross-sectional studies, case reports, case series, letters, reviews, and editorials. Duplicate reports.
Selection of studies for inclusion in the review
Articles will be identified by 1 clinical scientist and reviewed by another senior clinical scientist. Data will be evaluated by a statistician, and consensually retain studies to be included. Disagreements when existing will be solved by discussion.
Data extraction and management
Data will be extracted using a designed form. Two reviewers will independently extract data. The domains included study setting (title, follow-up time, design, and region), study population (age, gender, and ethnicity), method of ascertainment of AMD, and information on severity level of AMD.
Appraisal of methodological quality of included studies and risk of bias
Methodological quality for included studies will be evaluated using the 10-item rating scale (Table 2) . [6] Each item will be assigned a score of 1 (yes) or 0 (no), and each score will be summed across items to generate an overall study quality score. Included studies will be defined into 3 levels according to overall score as follows: low risk of bias (8-10), moderate risk (6-7), and high risk (0-5).
Data synthesis
Incidence of AMD was calculated as cumulative incidence including both early AMD and late AMD and any-AMD. According to included studies varied in time of follow-up, we calculated annual incidence of AMD using the formula Àln (1 À S)/t, where S is the proportion of new AMD cases over t years and t is the time of follow-up. [7] Similar to the incidence of AMD, we will calculate the cumulative progression and the annual progression estimates of AMD. We will perform subgroup analysis on the incidence of AMD by study region, population age and gender, follow-up duration, and method of ascertainment of AMD. We will also assess the effect of major risk factors for AMD incidence including age, gender, ethnicity, smoking, and others wherever data were available.
Assessment of reporting biases
The presence of publication and selective reporting bias will be assessed using symmetry of funnel plots and Egger's test. [8] Asymmetry of the funnel plot or a P value of Egger's regression test less than 0.05 will be considered indicative of significant publication bias.
Ethics and dissemination
Ethics approval is not required as this is a systematic review and meta-analysis using published data. We will report our findings of this systematic review and meta-analysis in a peer-reviewed journal in future.
Discussion
The burden of age-related diseases is increasing in China, as a common age-related eye disease, AMD is becoming a common cause of visual impairment and blindness in elder population. In this comprehensive systematic review and meta-analysis, we will include cohort studies regarding the incidence or progression of AMD worldwide. Moreover, this systematic review and metaanalysis will provide summarized data to establish global incidence or progression estimates and its risk factors. Furthermore, current systematic review and meta-analysis will project the number of people with AMD from 2030 to 2050 which will be a useful guide for public health strategies to control AMD.
Author contributions
Author contributions: L.L. developed the study protocol. S.Z. and X.W.L. developed the search strategy. J.Y.W. and S.Y. will scan the included studies. H.Z. and G.S.Z. extract the data and assess the risk of bias. L.L. will act as an arbiter if there is any disagreement in this study. L.S. and Q.W. will perform data analysis. All authors will contribute to data interpretation. S.Z.
Zhao et al. Medicine (2019) 98:10
Medicine Provide an explicit statement of the question (s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
5
Methods Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review 6
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 6
Search strategy 10 Present draft of search strategy to be used for at least 1 electronic database, including planned limits, such that it could be repeated 6
Study records: Data management 11a Describe the mechanism (s) that will be used to manage records and data throughout the review 6 Selection process 11b State the process that will be used for selecting studies (such as 2 independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
6
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 6 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any preplanned data assumptions and simplifications
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution License 4.0. 
